Certainly, immunotherapy has rapidly emerged as a promising approach for the treatment of cancer patients since remarkable clinical benefit has been observed with checkpoint inhibitors (CTLA-4, PD1 and PDL1 antibodies), adoptive cell therapy (TILs, CAR T-cells), and immunomodulating agents (chemotherapy, small molecules, etc.). Here, CD274 is linked to cancer.